GLOW and KLOW are two of the most popular multi-peptide research blends, and the names make them sound more different than they are. KLOW is GLOW with one extra peptide. Both contain GHK-Cu, BPC-157 and TB-500; KLOW adds KPV, a three-amino-acid fragment of alpha-MSH. This guide explains what each component is, what KPV adds, and what the published research does and does not cover.
All compounds discussed are sold for laboratory research use only. This page summarizes published research and is not guidance for human or veterinary use.
At a glance
| GLOW | KLOW | |
|---|---|---|
| Components | GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500, KPV |
| Number of peptides | 3 | 4 |
| Total per Rogue vial | 70 mg | 80 mg |
| The difference | – | Adds KPV (Lys-Pro-Val), the C-terminal tripeptide of alpha-MSH |
| Research areas of the components | Extracellular matrix and collagen (GHK-Cu), tendon and vascular models (BPC-157), actin and cell migration (TB-500) | All of GLOW’s, plus intestinal inflammation models (KPV) |
| Published studies on the full blend | None | None |
| Exact amount of each component | Listed on the batch COA | Listed on the batch COA |
Same base, one added peptide
The two blends share an identical three-peptide base. Every component of GLOW is also in KLOW. The only difference is KPV, which accounts for the higher total per vial (80 mg vs 70 mg). Because the base is shared, anything a lab learns about the GLOW components applies to that part of KLOW too. What changes is the extra variable KPV introduces.
The shared components
- GHK-Cu: a copper complex of the tripeptide glycyl-histidyl-lysine, first identified in human plasma (Pickart and Thaler, 1973). Its best-known research is in fibroblast cultures, where it stimulated collagen synthesis (Maquart et al., 1988), and in extracellular-matrix and gene-expression studies. See the GHK-Cu research overview.
- BPC-157: a synthetic 15-residue peptide derived from a gastric protein sequence. It is studied mostly in rodent tendon, wound and blood-vessel models (Chang et al., 2011; Seiwerth et al., 2014). See the BPC-157 research overview.
- TB-500: based on thymosin β4, an actin-binding protein found in most cell types. Its best-established function is sequestering actin monomers (Safer et al., 1991), and it has been studied in endothelial cell migration (Malinda et al., 1997). See the TB-500 research overview.
For a closer look at how BPC-157 and TB-500 compare to each other, see BPC-157 vs TB-500.
What KPV adds
KPV is the tripeptide lysine-proline-valine, residues 11 to 13 of alpha-melanocyte-stimulating hormone (alpha-MSH). At about 342 g/mol it is the smallest molecule in either blend. It is studied for a different reason than the other three: most of its literature is in models of intestinal inflammation.
- Uptake through PepT1: In intestinal epithelial cells, KPV is carried into the cell by the peptide transporter PepT1, and in mouse colitis models this uptake was linked to reduced inflammatory signaling (Dalmasso et al., 2008).
- Colitis models: A separate study found KPV reduced markers of inflammation in two mouse models of inflammatory bowel disease (Kannengiesser et al., 2008).
See the KPV research overview for the full literature.
Is there research on either blend?
Very little. A 2026 rat Achilles tendon study compared BPC-157, TB-500 and the two given together, and its authors described the results as exploratory (Biçer et al., 2026). We are not aware of any published study that tests GHK-Cu, BPC-157 and TB-500 together (GLOW) or adds KPV to that combination (KLOW). How the components interact in one preparation has not been measured.
How researchers choose between them
- Matrix, tendon or cell-migration models: GLOW contains the three components with literature in those areas, without adding a fourth variable.
- Models that also involve intestinal or inflammatory pathways: KLOW includes KPV, the component with published data in those models.
- Isolating one component’s contribution: single-peptide vials of GHK-Cu, BPC-157, TB-500 and KPV let a lab test each one alone before testing a blend.
- Fewer variables: every added peptide is another factor that could interact with the others, so many study designs start with the smaller blend.
What the research does not show
- The research on each component comes from cell culture and animal models. It does not establish any effect in humans.
- Findings for a single peptide cannot be assumed to hold when it is combined with others.
- No published work has examined GLOW or KLOW as a whole.
- None of the four components is an FDA-approved drug, and BPC-157 and TB-500 are on the WADA Prohibited List.
Verify what you’re working with
With three or four peptides in one vial, the COA needs to show each component separately, not just a total. Every Rogue batch is tested by an independent, ISO 17025 accredited U.S. lab, the batch COA lists the amount of each peptide, and the QR code on each vial opens that batch’s report on the lab’s own website. See how to read a peptide COA or browse the COA Library.
Full overviews of each blend: GLOW blend research and KLOW blend research.
References
- Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-87. PMID 4349963
- Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Lett. 1988;238(2):343-346. PMID 3169264
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID 21030672
- Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1121-1125. PMID 23782145
- Safer D, et al. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029-4032. PMID 1999398
- Malinda KM, et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. PMID 9194528
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID 18061177
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID 18092346
Compounds researchers often order together, 5% off as a set. Every vial ships with its batch COA.
GLP-3 RT + KLOWFrom $207.10 
BPC-157 + TB-500 + KLOWFrom $207.10 
KLOW + NAD+From $169.10